A phase 2 study of transcatheter aterial chemoembolization using cisplatin and DC beads for advanced hepatocellular carcinoma

A phase 2 study of transcatheter aterial chemoembolization using cisplatin and DC beads for advanced hepatocellular carcinoma - DEB-TACE(CDDP+DC beads)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000028000

Enrollment

Registered

2017-08-01

Start date

2017-07-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HCC

Interventions

Transcatheter arterial chemoembolization using cisplatin and DC beads

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Patients with HCC diagnosed by histological or crinical examinations. (2)HCC with enhancement in arterial phase of enhanced CT or MRI. (3)Child-Puge score of 7 or less. (4)multiple HCC or sigle HCC over 5cm diameter (5) PS 0-2 (6)patients aged 20 years or over. (7)HCC not capable of local therapy. (8)Patients with at least 4 weeks interval from previous local therapy or transcatheter therapy. (10)Patients who are expected to live more than 3 months.

Exclusion criteria

Exclusion criteria: (1)HCC without stain on angiogram. (2)History of hypersensitivity to cisplatinum-containing drug. (3)distant metastasis (4)main portal tumor thrombosis or hepatic vein tumor thrombosis (5)Patients with intrahepatic AP shunt or AV shunt. (6)Patients with complications to be treated preferentially. (7)Patients who can not keep their rest during the procedure. (8)Patients who are concluded to be inappropriate to participate in this study by their physicians.

Design outcomes

Primary

Measure	Time frame
Response rate(RR) 3 months after TACE	—

Secondary

Measure	Time frame
Safty Tumor markers	—

Countries

Japan

Contacts

Public ContactMasaki Ishikawa

National Hospital Organization KURE Medical Center Diagnostic radiology

ishikawam@kure-nh.go.jp0823-22-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026